NERVIANO, Italy, 28 July 2025 — NerPharMa (NPM), a renowned Contract Development and Manufacturing Organization (CDMO) specializing in oncology and in immunology, today announced the appointment of Serena Alvino, MBA, CIPP/E, as its new Chief Executive Officer, effective immediately.
With more than 20 years of international leadership experience across the life sciences sector, Ms. Alvino brings a strong track record in legal strategy, business development, and cross-border transactions. Her appointment marks a key step in NPM’s strategic evolution as a high-quality, innovation-driven CDMO serving global clients in oncology and beyond.
Prior to her current positions, Serena held senior leadership roles at Dompé Farmaceutici, where she oversaw global legal operations and was instrumental in several strategic milestones. She also advised on international venture transactions and built high-performing legal teams across multiple jurisdictions.
Hugues Dolgos, Pharm.D., Chairman of the NerPharMa Board commented: “Serena brings the right combination of business acumen, legal expertise, and leadership vision. Her appointment marks a new chapter for NerPharMa as we continue to grow our development and manufacturing services in a dynamic and highly regulated environment.”
Serena Alvino, CEO of NerPharMa, said: “I’m proud to take on this role at such a transformative time for the company. NerPharMa has established itself as a trusted partner in oncology and in immunology manufacturing. I look forward to working with our teams and clients to drive short term profitability, operational excellence, and long-term value.”
NerPharMa continues to strengthen its position as a highly specialized, agile and reliable CDMO partner, supporting clients from clinical development through commercial supply. Ms. Alvino will continue to serve as Chief Legal Officer and Member of the Board of Directors of Nerviano Medical Sciences Srl (NMS Srl), a clinical-stage biopharmaceutical company and Chief Executive Officer of BioNerviano, a service company that manages BioN campus in Nerviano, Italy. All three companies are part of the NMS Group.
